Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen ama1: Report on a phase 1a clinical trial

Molecular Therapy

Volumn 22, Issue 12, 2014, Pages 2142-2154

  Hodgson, Susanne H ^a   Choudhary, Prateek ^a   Elias, Sean C ^a   Milne, Kathryn H ^a   Rampling, Thomas W ^a   Biswas, Sumi ^a   Poulton, Ian D ^a   Miura, Kazutoyo ^b   Douglas, Alexander D ^a   Alanine, Daniel Gw ^a   Illingworth, Joseph J ^a   De Cassan, Simone C ^a   Zhu, Daming ^b   Nicosia, Alfredo ^c,e   Long, Carole A ^b   Moyle, Sarah ^d   Berrie, Eleanor ^a   Lawrie, Alison M ^a   Wu, Yimin ^b   Ellis, Ruth D ^b   Hill, Adrian V S ^a   Draper, Simon J ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Okairòs ^*  (Italy)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AGATOLIMOD; ALUMINUM HYDROXIDE; AMA1 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; PARASITE ANTIGEN; POXVIRUS VECTOR; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; OLIGODEOXYRIBONUCLEOTIDE;

ADULT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBRYO; EX VIVO STUDY; FEMALE; FEVER; GENETIC IMMUNIZATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOGENICITY; IN VITRO STUDY; INJECTION SITE PAIN; MALAISE; MALARIA; MALE; MYALGIA; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; SINGLE DRUG DOSE; SYSTEMIC DISEASE; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VACCINATION; ADMINISTRATION AND DOSAGE; CLINICAL TRIAL; GENE VECTOR; GENETICS; IMMUNIZATION; IMMUNOLOGY; MALARIA, FALCIPARUM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; ORTHOPOXVIRUS; SIMIAN VIRUS; YOUNG ADULT;

CHIMPANZEE ADENOVIRUS; ORTHOPOXVIRUS; PLASMODIUM FALCIPARUM;

ADENOVIRUSES, SIMIAN; ADJUVANTS, IMMUNOLOGIC; ADULT; ALUMINUM HYDROXIDE; ANTIGENS, PROTOZOAN; COMBINED MODALITY THERAPY; GENETIC VECTORS; HUMANS; IMMUNIZATION, SECONDARY; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; ORTHOPOXVIRUS; PLASMODIUM FALCIPARUM; VACCINATION; YOUNG ADULT;

EID: 84927173990     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.157     Document Type: Article

References (59)

1. World Health Organization. (2012). World Malaria Report 2012. World Malaria Report 2012: 1-249.
2. Murray, CJ, Rosenfeld, LC, Lim, SS, Andrews, KG, Foreman, KJ, Haring, D et al. (2012). Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379: 413-431.
3. Birkett, AJ, Moorthy, VS, Loucq, C, Chitnis, CE and Kaslow, DC (2013). Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities. Vaccine 31(suppl. 2): B233-B243.
4. Agnandji, ST, Lell, B, Fernandes, JF, Abossolo, BP, Methogo, BG, Kabwende, AL, et al. (2012). A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 367: 2284-2295.
5. Hill, AV (2011). Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci 366: 2806-2814.
6. Goodman, AL and Draper, SJ (2010). Blood-stage malaria vaccines - recent progress and future challenges. Ann Trop Med Parasitol 104: 189-211.
7. Miura, K, Zhou, H, Diouf, A, Moretz, SE, Fay, MP, Miller, LH et al. (2009). Antiapical- membrane-antigen-1 antibody is more effective than anti-42-kilodaltonmerozoite- surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 16: 963-968.
8. Cheru, L, Wu, Y, Diouf, A, Moretz, SE, Muratova, OV, Song, G et al. (2010). The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species. Vaccine 28: 4423-4429.
9. Ellis, RD, Sagara, I, Doumbo, O and Wu, Y (2010). Blood stage vaccines for Plasmodium falciparum: current status and the way forward. Hum Vaccin 6: 627-634.
10. Targett, GA and Greenwood, BM (2008). Malaria vaccines and their potential role in the elimination of malaria. Malar J 7(suppl. 1): S10.
11. Roestenberg, M, Remarque, E, de Jonge, E, Hermsen, R, Blythman, H, Leroy, O et al. (2008). Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One 3: e3960.
12. Wu, Y, Ellis, RD, Shaffer, D, Fontes, E, Malkin, EM, Mahanty, S et al. (2008). Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 3: e2636.
13. Schubert, C (2009). Boosting our best shot. Nat Med 15: 984-988.
14. Podda, A and Del Giudice, G (2003). MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2: 197-203.
15. Alving, CR, Peachman, KK, Rao, M and Reed, SG (2012). Adjuvants for human vaccines. Curr Opin Immunol 24: 310-315.
16. Coler, RN, Carter, D, Friede, M and Reed, SG (2009). Adjuvants for malaria vaccines. Parasite Immunol 31: 520-528.
17. Draper, SJ, Moore, AC, Goodman, AL, Long, CA, Holder, AA, Gilbert, SC et al. (2008). Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14: 819-821.
18. de Cassan, SC and Draper, SJ (2013). Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Rev Vaccines 12: 365-378.
19. Draper, SJ and Heeney, JL (2010). Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8: 62-73.
20. Capone, S, DAlise, AM, Ammendola, V, Colloca, S, Cortese, R, Nicosia, A et al. (2013). Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines 12: 379-393.
21. Sheehy, SH, Duncan, CJ, Elias, SC, Collins, KA, Ewer, KJ, Spencer, AJ et al. (2011). Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 19: 2269-2276.
22. Sheehy, SH, Duncan, CJ, Elias, SC, Biswas, S, Collins, KA, OHara, GA et al. (2012). Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 7: e31208.
23. Elias, SC, Choudhary, P, de Cassan, SC, Biswas, S, Collins, KA, Halstead, FD et al. (2014). Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. Immunology 141: 628-644.
24. Sheehy, SH, Duncan, CJ, Elias, SC, Choudhary, P, Biswas, S, Halstead, FD et al. (2012). ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 20: 2355-2368.
25. Douglas, AD, de Cassan, SC, Dicks, MD, Gilbert, SC, Hill, AV and Draper, SJ (2010). Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28: 7167-7178.
26. Draper, SJ, Biswas, S, Spencer, AJ, Remarque, EJ, Capone, S, Naddeo, M et al. (2010). Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol 185: 7583-7595.
27. de Cassan, SC, Forbes, EK, Douglas, AD, Milicic, A, Singh, B, Gupta, P et al. (2011). The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J Immunol 187: 2602-2616.
28. Gmez-Romn, VR, Florese, RH, Peng, B, Montefiori, DC, Kalyanaraman, VS, Venzon, D et al. (2006). An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J Acquir Immune Defic Syndr 43: 270-277.
29. Vinner, L, Therrien, D, Wee, E, Laursen, I, Hanke, T, Corbet, SL et al. (2006). Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1. APMIS 114: 690-699.
30. Shu, Y, Winfrey, S, Yang, ZY, Xu, L, Rao, SS, Srivastava, I et al. (2007). Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25: 1398-1408.
31. Zolla-Pazner, S, Lubeck, M, Xu, S, Burda, S, Natuk, RJ, Sinangil, F et al. (1998). Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J Virol 72: 1052-1059.
32. Patterson, LJ, Malkevitch, N, Pinczewski, J, Venzon, D, Lou, Y, Peng, B et al. (2003). Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/ or nef vaccines and boosted with SIV gp120. J Virol 77: 8607-8620.
33. Stewart, VA, McGrath, SM, Dubois, PM, Pau, MG, Mettens, P, Shott, J et al. (2007). Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS, S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect Immun 75: 2283-2290.
34. Hutchings, CL, Birkett, AJ, Moore, AC and Hill, AV (2007). Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect Immun 75: 5819-5826.
35. Duncan, CJ, Sheehy, SH, Ewer, KJ, Douglas, AD, Collins, KA, Halstead, FD et al. (2011). Impact on malaria parasite multiplication rates in infected volunteers of the protein-inadjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One 6: e22271.
36. Mullen, GE, Ellis, RD, Miura, K, Malkin, E, Nolan, C, Hay, M et al. (2008). Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One 3: e2940.
37. Ellis, RD, Mullen, GE, Pierce, M, Martin, LB, Miura, K, Fay, MP et al. (2009). A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine 27: 4104-4109.
38. Draper, SJ, Cottingham, MG and Gilbert, SC (2013). Utilizing poxviral vectored vaccines for antibody induction-progress and prospects. Vaccine 31: 4223-4230.
39. Reed, SG, Bertholet, S, Coler, RN and Friede, M (2009). New horizons in adjuvants for vaccine development. Trends Immunol 30: 23-32.
40. Rerks-Ngarm, S, Pitisuttithum, P, Nitayaphan, S, Kaewkungwal, J, Chiu, J, Paris, R, et al. (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
41. Borthwick, N, Ahmed, T, Ondondo, B, Hayes, P, Rose, A, Ebrahimsa, U et al. (2014). Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 22: 464-475.
42. Pierce, MA, Ellis, RD, Martin, LB, Malkin, E, Tierney, E, Miura, K et al. (2010). Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Vaccine 28: 2236-2242.
43. Miura, K, Zhou, H, Moretz, SE, Diouf, A, Thera, MA, Dolo, A et al. (2008). Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. J Immunol 181: 8776-8783.
44. Malkin, EM, Diemert, DJ, McArthur, JH, Perreault, JR, Miles, AP, Giersing, BK et al. (2005). Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 73: 3677-3685.
45. Crompton, PD, Mircetic, M, Weiss, G, Baughman, A, Huang, CY, Topham, DJ et al. (2009). The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparumspecific memory B cells in malaria-naive individuals. J Immunol 182: 3318-3326.
46. Traore, B, Kon, Y, Doumbo, S, Doumtab, D, Traor, A, Crompton, PD et al. (2009). The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali. Vaccine 27: 7299-7303.
47. Wrammert, J, Smith, K, Miller, J, Langley, WA, Kokko, K, Larsen, C et al. (2008). Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453: 667-671.
48. Miura, K, Zhou, H, Diouf, A, Tullo, G, Moretz, SE, Aebig, JA et al. (2011). Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized. Vaccine 29: 2255-2261.
49. Spring, MD, Cummings, JF, Ockenhouse, CF, Dutta, S, Reidler, R, Angov, E et al. (2009). Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One 4: e5254.
50. Thera, MA, Doumbo, OK, Coulibaly, D, Laurens, MB, Ouattara, A, Kone, AK et al. (2011). A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365: 1004-1013.
51. Srinivasan, P, Ekanem, E, Diouf, A, Tonkin, ML, Miura, K, Boulanger, MJ et al. (2014). Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. Proc Natl Acad Sci USA 111: 10311-10316.
52. Sheehy, SH, Douglas, AD and Draper, SJ (2013). Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines. Hum Vaccin Immunother 9: 1831-1840.
53. Duncan, CJ, Hill, AV and Ellis, RD (2012). Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum Vaccin Immunother 8: 706-714.
54. Sagara, I, Ellis, RD, Dicko, A, Niambele, MB, Kamate, B, Guindo, O et al. (2009). A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semiimmune Malian adults. Vaccine 27: 7292-7298.
55. Paradiso, P (2009). Essential criteria for evaluation of pneumococcal conjugate vaccine candidates. Vaccine 27(suppl. 3): C15-C18.
56. Biswas, S, Dicks, MD, Long, CA, Remarque, EJ, Siani, L, Colloca, S et al. (2011). Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS One 6: e20977.
57. Kennedy, MC, Wang, J, Zhang, Y, Miles, AP, Chitsaz, F, Saul, A et al. (2002). In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun 70: 6948-6960.
58. Williams, AR, Douglas, AD, Miura, K, Illingworth, JJ, Choudhary, P, Murungi, LM et al. (2012). Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. PLoS Pathog 8: e1002991.
59. Bushell, KM, Sllner, C, Schuster-Boeckler, B, Bateman, A and Wright, GJ (2008). Large-scale screening for novel low-affinity extracellular protein interactions. Genome Res 18: 622-630.